Kynexis
Emilyne Blattes is a professional with a strong background in research and development within the pharmaceutical industry. Emilyne has experience in various roles such as R&D Leader, R&D Manager, Regulatory Manager, and Global Clinical Project Manager. Emilyne has worked with companies such as 2 Bridge, Kynexis, and iM4TB, bringing their expertise in scientific development, regulatory operations, and clinical trials management. Emilyne holds a Doctor of Philosophy in Biochemistry and a Diploma of Advanced Studies in Management of Clinical Trials.
This person is not in any offices
Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.